中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

73 records (took 0.04 seconds)

    NANOFORMULATION OF MUSK-DERIVED BIOACTIVE INGREDIENTS FOR NANOCOSMETIC APPLICATIONS
    16.
    发明申请
    NANOFORMULATION OF MUSK-DERIVED BIOACTIVE INGREDIENTS FOR NANOCOSMETIC APPLICATIONS 审中-公开
    用于纳米应用的MUSK衍生的生物成分的纳米化

    公开(公告)号：US20150223451A1

    公开(公告)日：2015-08-13

    申请号：US14614849

    申请日：2015-02-05

    Applicant: Shaker A. Mousa ,  Amna Saddiq

    Inventor： Shaker A. Mousa ,  Amna Saddiq

    IPC: A01N25/10

    CPC classification number: A01N25/28 ,  A01N35/04 ,  A01N63/02

    Abstract: The composition of the Nano carrier or Nano polymers composed of Hyaluronic Acid (15-25%) and fatty acids (50-70%) cross linked with ultra-Low molecular weight chitosan (15-25%) encapsulating isolated compounds from musk and their combinations for cosmetic use as anti-aging, anti-microbial, and fragrance. Additionally, these nano-encapsulated Musk bioactive compounds (MBC) at 0.1-10% (w/w MBC/Nano polymers) could be used in textile manufacturing (carpet/rugs and clothes) to provide anti-microbial and fragrance properties. Furthermore, Musk derived products are chemically conjugated to HA polymer, FA polymer, CH polymer, HA-CH co-polymer, FA-CH co-polymer or HA-CH-FA co-polymer to be incorporated into the fabric of the textile products (carpet/rugs or clothes).

    Abstract translation: 由透明质酸（15-25％）和脂肪酸（50-70％）组成的纳米载体或纳米聚合物的组合物与超低分子量壳聚糖（15-25％）交联，从麝香和其他物质中包裹分离的化合物 化妆品用作抗老化，抗微生物和香料的组合。 另外，0.1-10％（w / w MBC /纳米聚合物）的这些纳米包裹的麝香生物活性化合物（MBC）可用于纺织品制造（地毯/地毯和衣服），以提供抗微生物和香料特性。 此外，麝香衍生物与HA聚合物，FA聚合物，CH聚合物，HA-CH共聚物，FA-CH共聚物或HA-CH-FA共聚物化学键合，以结合到纺织品的织物中 （地毯/地毯或衣服）。

    METHOD AND COMPOSITION OF GLYCOSAMINOGLYCANS IN SICKLE CELL AND VASCULAR DISORDERS
    17.
    发明申请
    METHOD AND COMPOSITION OF GLYCOSAMINOGLYCANS IN SICKLE CELL AND VASCULAR DISORDERS 审中-公开
    谷氨酸蛋白酶在镰状细胞和血管疾病中的方法与组成

    公开(公告)号：US20150150818A1

    公开(公告)日：2015-06-04

    申请号：US14526950

    申请日：2014-10-29

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/48 ,  A61K47/42 ,  A61K47/36 ,  A61K31/737

    CPC classification number: A61K31/737 ,  A61K9/5169 ,  A61K47/6939

    Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.

    Abstract translation: 包含纳米颗粒的组合物。 纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳。 壳包括聚L-精氨酸。 SNACH离子或共价键合到聚L-精氨酸。 用于治疗受试者疾病的方法包括：向受试者施用治疗有效量的用于治疗病症的组合物。 该疾病是血管疾病，血管疾病的并发症或其组合。

    OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS
    18.
    发明申请
    OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS 审中-公开
    血管生成介导的疾病中的OCULAR NANOFORMULATION和使用方法

    公开(公告)号：US20150140106A1

    公开(公告)日：2015-05-21

    申请号：US14526738

    申请日：2014-10-29

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K9/50 ,  A61K45/06 ,  A61K47/48 ,  A61K31/727 ,  A61K9/00

    CPC classification number: A61K9/5036 ,  A61K9/0048 ,  A61K9/5026 ,  A61K9/5146 ,  A61K9/5153 ,  A61K9/5161 ,  A61K31/727 ,  A61K45/06 ,  A61K47/6933

    Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.

    Abstract translation: 包括纳米颗粒的眼用制剂。 每个纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳，具有或不具有疏水性抗血管生成酪氨酸激酶抑制剂。 SNACH离子或共价键合到壳上。 壳包括选自聚（乳酸 - 共 - 乙醇酸）（PLGA），壳聚糖，壳聚糖 - 藻酸盐和NIPAAM-APMAH-AA的聚合物，其中NIPAAM是N-异丙基丙烯酰胺，APMAH是N-3 氨基丙基甲基丙烯酰胺盐酸盐，AA是丙烯酸。 用于治疗受试者的眼睛疾病的方法包括：向患者的眼睛施用治疗有效量的用于治疗眼睛疾病的眼用制剂。 眼病涉及眼血管生成介导的病症。

    Formulations of factor VIIa inhibitors and utility
    20.
    发明授权
    Formulations of factor VIIa inhibitors and utility 有权
    因子VIIa抑制剂和效用的制剂

    公开(公告)号：US08481479B1

    公开(公告)日：2013-07-09

    申请号：US13414106

    申请日：2012-03-07

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K38/00 ,  A61K38/05 ,  C07K14/755

    CPC classification number: A61K38/4846 ,  A61K9/1273 ,  A61K9/19 ,  A61K9/5146 ,  A61K47/6935 ,  A61K47/6939 ,  C12N9/6437

    Abstract: A nanoparticle, a chemical structure, and a treatment method for treating a patient having a disorder. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to or encapsulated in the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The treatment method administers a therapeutic effective amount of the nanoparticle or chemical structure to the patient to treat the disorder. The disorder may be a vascular disorder, pulmonary hypertension, cardiac insufficiency, a neurological disorder, and combinations thereof.

    Abstract translation: 纳米颗粒，化学结构和用于治疗患有病症的患者的治疗方法。 纳米颗粒包括聚L-精氨酸聚合物和与聚L-精氨酸聚合物缀合或包封的因子VIIa抑制因子。 该化学结构包括包含至少一种一氧化氮（NO）供体的因子VIIa抑制剂。 治疗方法向患者施用治疗有效量的纳米颗粒或化学结构以治疗该病症。 该病症可以是血管疾病，肺动脉高压，心功能不全，神经障碍及其组合。

Patent Agency Ranking